1.94
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
ACXP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ACXP Stock Chart | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
ACXP Stock Price, Quote & Chart | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat - ACCESS Newswire
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat | FinancialContent - FinancialContent
Earnings call transcript: Acurx Pharmaceuticals Q1 2026 sees EPS miss, stock dips - Investing.com Australia
Acurx outlines August first patient for 20-patient rCDI pilot as it weighs FDA one-trial path - MSN
Acurx Pharmaceuticals stock (US00366D1037): reverse split and price swings keep biotech in focus - AD HOC NEWS
Acurx (ACXP) Q1 2026 Earnings Transcript - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Acurx Pharmaceuticals (ACXP), Neurogene (NGNE) - The Globe and Mail
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Maxim Group Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2026 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals (ACXP) registers 1.3M shares for Lincoln Park resale - Stock Titan
Acurx Pharmaceuticals (NASDAQ: ACXP) registers 1.65M resale shares - Stock Titan
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
ACURX PHARMACEUTICALS ($ACXP) Releases Q1 2026 Earnings - Quiver Quantitative
Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 Results and Provides Business Update - Moomoo
[EFFECT] Acurx Pharmaceuticals, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Acurx Pharmaceuticals (ACXP) trims Q1 loss but flags going-concern risk - Stock Titan
ACXP Q1'26 Earnings: EPS estimate is (1.20) USD - TradingView
ACXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
The growth story Acurx (ACXP) is not telling investors (Smart Money Outflows) 2026-05-08Crowd Entry Signals - newser.com
Acurx Pharmaceuticals Inc expected to post a loss of 63 cents a shareEarnings Preview - TradingView
Number of shareholders of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
1.65M ACXP warrant shares registered for resale by Acurx (NASDAQ: ACXP) - Stock Titan
Acurx (NASDAQ: ACXP) files S-1 to register 1.3M Lincoln Park resale shares - Stock Titan
Mouse study links Acurx antibiotics to MRSA drop, gut microbes preserved - Stock Titan
Can Acurx Pharmaceuticals (ACXP) climb 226.3% to reach the level Wall Street analysts expect? - MSN
Replay to follow Acurx CEO's virtual A.G.P. healthcare fireside chat - Stock Titan
Is Acurx Pharmaceuticals (ACXP) stock outpacing its medical peers this year? - MSN
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit - The Globe and Mail
Acurx takes Wall Street stage at 48 Wall St. investor summit - Stock Titan
Acurx Pharmaceuticals announces up to $7.1M offering - MSN
ACXP Forecast, Price Target & Analyst Ratings | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
ACXP (Acurx Pharmaceuticals Inc.) posts far stronger Q4 2025 EPS than analyst estimates, but shares fall 4.42 percent today.Consensus Beat - UBND thành phố Hải Phòng
Acurx (ACXP) director Carl Sailer awarded 2,150 stock options at $2.36 - Stock Titan
Acurx (NASDAQ: ACXP) director gets 2,150 stock options grant - Stock Titan
Acurx Pharmaceuticals (ACXP) director awarded 2,150 stock options as board pay - Stock Titan
Acurx Pharmaceuticals (ACXP) director awarded 2,150 stock options at $2.36 strike - Stock Titan
Acurx Pharmaceuticals (ACXP) director receives 2,150 stock options grant - Stock Titan
Acurx Pharmaceuticals (ACXP) director awarded 37,100 stock options at $2.36 - Stock Titan
Acurx Pharmaceuticals (ACXP) CEO awarded 37,100 stock options at $2.36 - Stock Titan
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):